<?xml version="1.0" encoding="UTF-8"?>
<p>Upon release of the first SARS-CoV-2 main protease structure (Mpro) to the Protein Data Bank, on March 2020, several in silico studies have been conducted to find potent protease inhibitors [
 <xref rid="B9-molecules-25-02529" ref-type="bibr">9</xref>,
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>,
 <xref rid="B11-molecules-25-02529" ref-type="bibr">11</xref>,
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>,
 <xref rid="B13-molecules-25-02529" ref-type="bibr">13</xref>,
 <xref rid="B14-molecules-25-02529" ref-type="bibr">14</xref>,
 <xref rid="B15-molecules-25-02529" ref-type="bibr">15</xref>,
 <xref rid="B16-molecules-25-02529" ref-type="bibr">16</xref>,
 <xref rid="B17-molecules-25-02529" ref-type="bibr">17</xref>,
 <xref rid="B18-molecules-25-02529" ref-type="bibr">18</xref>,
 <xref rid="B19-molecules-25-02529" ref-type="bibr">19</xref>]. The in silico-evaluated compounds were mostly approved drugs of all categories [
 <xref rid="B9-molecules-25-02529" ref-type="bibr">9</xref>,
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>,
 <xref rid="B11-molecules-25-02529" ref-type="bibr">11</xref>,
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>,
 <xref rid="B13-molecules-25-02529" ref-type="bibr">13</xref>,
 <xref rid="B14-molecules-25-02529" ref-type="bibr">14</xref>,
 <xref rid="B15-molecules-25-02529" ref-type="bibr">15</xref>,
 <xref rid="B16-molecules-25-02529" ref-type="bibr">16</xref>,
 <xref rid="B17-molecules-25-02529" ref-type="bibr">17</xref>,
 <xref rid="B18-molecules-25-02529" ref-type="bibr">18</xref>,
 <xref rid="B19-molecules-25-02529" ref-type="bibr">19</xref>], and natural plant [
 <xref rid="B11-molecules-25-02529" ref-type="bibr">11</xref>,
 <xref rid="B13-molecules-25-02529" ref-type="bibr">13</xref>] as well as marine [
 <xref rid="B16-molecules-25-02529" ref-type="bibr">16</xref>] products. Since docking analysis was performed, in most cases, in randomly selected approved drugs, independently of the rational of their initial design and their initial target, pharmaceutical agents of different drug categories have been proposed. Among the most potent predicted inhibitors were anti-bacterial [
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>,
 <xref rid="B19-molecules-25-02529" ref-type="bibr">19</xref>], anti-fungal [
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>], anti-viral [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>], anti-tuberculosis [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>], anti-nimatoid [
 <xref rid="B17-molecules-25-02529" ref-type="bibr">17</xref>], anti-protozoal [
 <xref rid="B17-molecules-25-02529" ref-type="bibr">17</xref>], anti-helminthic [
 <xref rid="B19-molecules-25-02529" ref-type="bibr">19</xref>], anti-inflammatory [
 <xref rid="B19-molecules-25-02529" ref-type="bibr">19</xref>], anti-tumor [
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>,
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>], vasodilator [
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>] vasoprotective [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>], anti-convulsant [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>], bronchodilator [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>], anti-psychotic [
 <xref rid="B10-molecules-25-02529" ref-type="bibr">10</xref>] agents and vitamins [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>]. Among the anti-viral agents are ribavirin, a nucleoside analogue used for the treatment of Lassa fever virus, influenza A and B and HCV [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>]; telbivudine, a nucleoside analogue used for the treatment of HAV [
 <xref rid="B12-molecules-25-02529" ref-type="bibr">12</xref>]; the HIV-1 integrase inhibitors raltegravir and dolutegravir [
 <xref rid="B13-molecules-25-02529" ref-type="bibr">13</xref>] and the HIV-1 protease inhibitors, darunavir and saquinavir [
 <xref rid="B14-molecules-25-02529" ref-type="bibr">14</xref>]. According to a more recent in silico research, published on April 15th, the HCV protease inhibitors, simeprevir and faldaprevir as well as the HIV-1 protease inhibitors indinavir and tipranavir along with saquinavir were predicted to act as better Mpro inhibitors compared to the lopinavir and ritonavir used in clinical practice [
 <xref rid="B15-molecules-25-02529" ref-type="bibr">15</xref>]. Danoprevir was the first anti-HCV protease inhibitor which was approved for clinical trials (clinical trial: NCT04291729).
</p>
